HTGF | High-Tech Gruenderfonds
High-Tech Gründerfonds Management GmbH is a venture capital firm based in Bonn, Germany, specializing in early-stage investments in high-tech startups. Established in 2005, the firm focuses on technology-driven companies across various sectors, including information and communication technology, life sciences, healthcare, automation, and cleantech. HTGF typically invests in companies that have been operational for no more than one year, aiming to contribute up to €0.6 million in initial funding and up to €3 million in follow-on financing. The firm seeks a minority stake, generally around 15%, and provides a subordinated loan convertible into equity, with deferred interest for up to four years to support liquidity. With a total investment volume of approximately €895.5 million across three funds, HTGF has successfully supported over 500 startups and attracted more than €2 billion in follow-on investments from external sources. The firm's investors include notable public and private entities, underscoring its role as a key player in fostering innovation and growth within the German startup ecosystem.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Medical Devices
Avelios Medical
Series A in 2025
Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform provides comprehensive support for healthcare staff, streamlining their daily tasks and fostering the integration of advanced technologies. By incorporating innovations such as artificial intelligence, big data, telemedicine, patient applications, and wearables, Avelios Medical aims to fundamentally transform healthcare delivery and research. This approach not only automates various operational processes but also enhances the overall efficiency and effectiveness of hospitals and clinics.
Laclarée
Seed Round in 2025
Laclarée is a French company based in Lyon, founded in 2016, that specializes in developing adaptive eyeglasses specifically designed to correct presbyopia. The company's innovative product incorporates patented fluid technology, allowing the eyeglasses to automatically adjust to different viewing distances in real-time. This advancement aims to address the needs of individuals aged 45 and older who are often dissatisfied with traditional vision correction solutions, such as progressive lenses or the use of multiple pairs of glasses. By combining adaptive lens technology with refractive correction capabilities for conditions like astigmatism, myopia, and hyperopia, Laclarée seeks to provide a more effective solution for clear vision across various distances.
Lindis Blood Care
Venture Round in 2024
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.
Doctorflix
Seed Round in 2024
Doctorflix is a medical education platform designed for healthcare professionals seeking to enhance their knowledge and skills in treatment methods. The platform focuses on simplifying and democratizing the exchange of medical knowledge by connecting doctors, hospitals, and pharmaceutical companies. It offers a diverse array of content, including on-demand videos, live events, articles, and podcasts, facilitating the transformation of theoretical knowledge into practical applications. With a commitment to advancing professional development, Doctorflix aims to accelerate the continuing education of medical professionals worldwide, leveraging its expertise in both the medical and technological sectors to deliver effective training solutions.
Sedivention
Pre Seed Round in 2024
Sedivention is a medical technology company specializing in the development of minimally invasive devices for obesity treatment. Their flagship product is a cryo catheter that, in a single, brief procedure akin to a gastroscopy, freezes and ablates the gastric branches of the vagus nerve, reducing hunger and promoting weight loss. This outpatient procedure offers a less invasive alternative to traditional obesity treatments.
Mediaire
Venture Round in 2024
Mediaire GmbH is a Berlin-based company founded in 2018 that specializes in software solutions for medical imaging. Its flagship application, md.Brain, focuses on quantitative brain volumetry, facilitating early detection of senile dementia and the automated measurement of medullary lesions in multiple sclerosis patients. By leveraging artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, providing precise examination results and diagnostic suggestions. The software is designed to improve both the quality and speed of diagnostic and therapeutic procedures, making it a valuable tool for healthcare centers and radiologists.
Nuuron
Seed Round in 2024
Nuuron is a neurotechnology company specializing in the development of a non-invasive, photonic neurostimulation device called the Memory-Pacemaker. This device is designed to help Alzheimer's patients store and retrieve memories by activating the memory center in the brain via the retina, acting as a computer-brain interface. The company's proprietary platform algorithms generate ultra-high frequency, digital photonic stimuli to achieve this.
Lymphatica Medtech
Series B in 2024
Lymphatica Medtech SA is a Swiss company that specializes in the design and manufacture of medical devices aimed at treating lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed innovative solutions such as the LymphoDrain system, which includes an active implantable lymphatic bypass that integrates a magnetically controlled micropump and subcutaneous catheters. This technology is designed to re-establish lymphatic circulation by internally draining lymphatic fluid from multiple points in the affected limb, providing a minimally invasive remedy for patients suffering from lymphedema. Lymphatica Medtech's commitment to advancing treatment options in this field reflects its focus on improving patient outcomes through cutting-edge medical technology.
ABH Optics
Pre Seed Round in 2024
ABH Optics specializes in manufacturing high-quality, ultra-thin and lightweight eyeglass lenses. Their innovative lenses, designed for high myopia patients, offer enhanced comfort and aesthetic appeal without compromising vision correction. This is achieved through a proprietary material that enables significant reduction in lens thickness and weight compared to traditional lenses.
CustomSurg
Seed Round in 2024
CustomSurg is a company focused on enhancing the treatment of complex bone fractures, particularly those involving joints. It develops fracture-specific bone plates that are tailored to match the unique anatomy of individual patients using advanced technologies such as computer tomography and 3D printing. This personalized approach provides improved stability for bone repairs, which can significantly reduce surgery time and lower long-term healthcare costs for patients. By offering a software solution for optimized surgical planning and designing patient-specific implants and instruments, CustomSurg shifts the treatment strategy from a subjective to an objective framework, aiming to improve outcomes for approximately 400,000 trauma patients in a market valued at $1.2 billion. The involvement of a Harvard Medical School surgeon in directing the medical aspects of the company adds a layer of credibility to its innovative offerings.
Altavo
Series A in 2024
Altavo is a medical device company that leverages machine learning and advanced sensor technology to enhance the lives of individuals who have lost their voice. It specializes in creating custom, natural-sounding artificial voices for people with speech disorders, enabling them to communicate more effectively.
RAYDIAX
Seed Round in 2023
RAYDIAX is a manufacturer of advanced therapy-assist computed tomography (CT) systems aimed at enhancing the quality of minimally invasive medical interventions, particularly for tumor treatments. The company develops imaging solutions that integrate a navigation system with both 2D and 3D X-ray live imaging, enabling healthcare providers to perform procedures with greater safety and efficiency. RAYDIAX's technology is designed to reduce the risk of postoperative complications, ultimately resulting in shorter hospital stays and quicker recovery times for patients. Through its innovative approach, RAYDIAX seeks to improve outcomes for both patients and clinicians in the realm of cancer therapy.
Kranus Health
Series A in 2023
Kranus Health is a global leader in virtual care for urology. It focuses on developing and providing clinically validated therapies for various urological conditions, ranging from andrology to uro-oncology.
InContAlert
Pre Seed Round in 2023
InContAlert is a deep tech company innovating in the field of incontinence management. It develops an mHealth device that monitors urinary bladder filling levels using advanced algorithms. The device sends alerts to users and caregivers when predefined thresholds are reached, minimizing risks associated with uncontrolled urine loss or bladder distension.
Doctorflix
Seed Round in 2023
Doctorflix is a medical education platform designed for healthcare professionals seeking to enhance their knowledge and skills in treatment methods. The platform focuses on simplifying and democratizing the exchange of medical knowledge by connecting doctors, hospitals, and pharmaceutical companies. It offers a diverse array of content, including on-demand videos, live events, articles, and podcasts, facilitating the transformation of theoretical knowledge into practical applications. With a commitment to advancing professional development, Doctorflix aims to accelerate the continuing education of medical professionals worldwide, leveraging its expertise in both the medical and technological sectors to deliver effective training solutions.
Refined Laser Systems
Seed Round in 2023
Refined Laser Systems is a specialized manufacturer of biophotonics devices, focusing on stain-free tissue diagnostics using its proprietary fiber-based tunable picosecond laser technology. The company's innovative laser systems enable rapid and reliable diagnoses, significantly reducing the time required compared to traditional methods.
FaCellitate
Seed Round in 2022
FaCellitate is a developer of innovative biomedical technology focused on enhancing cancer and stem cell research, drug discovery, toxicology, and tissue engineering. The company specializes in creating polymeric platforms that provide chemically defined, animal- and xeno-free cell culture coatings. These advanced coatings facilitate improved cellular interactions, thereby significantly enhancing cell culture practices in biological research. By offering smart lab surfaces, FaCellitate enables researchers to conduct more effective experiments, contributing to advancements in various fields of biomedical research.
C-mo Medical Solutions
Seed Round in 2022
C-mo Medical Solutions specializes in developing innovative monitoring devices aimed at comprehensively assessing patients' cough patterns. The company's portable and ergonomic wearables are designed for long monitoring periods, allowing for extensive data collection on distinctive cough characteristics. Through fully automated analysis, these devices enable healthcare professionals to deliver accurate diagnoses and create personalized treatment plans for patients. C-mo's solutions address key use cases throughout the patient management lifecycle, ensuring that both patients and clinicians benefit from enhanced diagnostic capabilities in the realm of respiratory health.
Kranus Health
Series A in 2022
Kranus Health is a global leader in virtual care for urology. It focuses on developing and providing clinically validated therapies for various urological conditions, ranging from andrology to uro-oncology.
Lindis Blood Care
Venture Round in 2022
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.
Altavo
Seed Round in 2022
Altavo is a medical device company that leverages machine learning and advanced sensor technology to enhance the lives of individuals who have lost their voice. It specializes in creating custom, natural-sounding artificial voices for people with speech disorders, enabling them to communicate more effectively.
Nebula Biocides
Seed Round in 2021
Nebula Biocides is a company that specializes in the development of innovative disinfection solutions aimed at effectively combating infection. The company focuses on creating application-oriented products that target persistent bacterial spores and resilient viruses, ensuring comprehensive protection for users in various environments. Nebula Biocides offers a range of smart disinfection devices designed to deliver reliable and efficient disinfection, making them suitable for diverse applications. Through its commitment to effective infection control, Nebula Biocides strives to enhance public health and safety by providing advanced disinfection technologies.
Avelios Medical
Seed Round in 2021
Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform provides comprehensive support for healthcare staff, streamlining their daily tasks and fostering the integration of advanced technologies. By incorporating innovations such as artificial intelligence, big data, telemedicine, patient applications, and wearables, Avelios Medical aims to fundamentally transform healthcare delivery and research. This approach not only automates various operational processes but also enhances the overall efficiency and effectiveness of hospitals and clinics.
ReActive Robotics
Venture Round in 2021
Founded in 2015, ReActive Robotics designs, manufactures, and sells rehabilitation robots for early movement rehabilitation post neurological injury or orthopedic surgery. Its robots aid in gait rehabilitation for neurological patients and joint replacement recovery.
Kranus Health
Seed Round in 2021
Kranus Health is a global leader in virtual care for urology. It focuses on developing and providing clinically validated therapies for various urological conditions, ranging from andrology to uro-oncology.
Mediaire
Seed Round in 2020
Mediaire GmbH is a Berlin-based company founded in 2018 that specializes in software solutions for medical imaging. Its flagship application, md.Brain, focuses on quantitative brain volumetry, facilitating early detection of senile dementia and the automated measurement of medullary lesions in multiple sclerosis patients. By leveraging artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, providing precise examination results and diagnostic suggestions. The software is designed to improve both the quality and speed of diagnostic and therapeutic procedures, making it a valuable tool for healthcare centers and radiologists.
Lymphatica Medtech
Series A in 2020
Lymphatica Medtech SA is a Swiss company that specializes in the design and manufacture of medical devices aimed at treating lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed innovative solutions such as the LymphoDrain system, which includes an active implantable lymphatic bypass that integrates a magnetically controlled micropump and subcutaneous catheters. This technology is designed to re-establish lymphatic circulation by internally draining lymphatic fluid from multiple points in the affected limb, providing a minimally invasive remedy for patients suffering from lymphedema. Lymphatica Medtech's commitment to advancing treatment options in this field reflects its focus on improving patient outcomes through cutting-edge medical technology.
WISE
Series C in 2020
WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper.
NovaPump
Series A in 2020
NovaPump specializes in developing non-invasive and percutaneous heart assist devices. Its flagship product is PERKAT, a self-expanding heart pump designed for acute left or right heart patients. PERKAT complements existing intra-aortic balloon pumps and offers advantages such as high pump performance, cost-effectiveness, and ECG triggering.
Kumovis
Series A in 2020
Kumovis is a medical technology company that specializes in developing a 3D printing system designed for both industrial and medical applications. The company focuses on the processing of high-performance polymers to create patient-customized implants. By integrating clean room technology into its 3D printing solutions, Kumovis enables hospitals to perform medical operations more conveniently and effectively, enhancing the overall quality of care.
Biograil
Seed Round in 2020
Biograil, founded in 2019 and led by CEO Karsten Lindhardt, is a medical device company focused on developing innovative delivery systems for biologic substances. The company has designed a device that is encapsulated in a standard-sized capsule, utilizing injection molding technology. This device eliminates mechanical moving components and harnesses the body's natural peristaltic forces to facilitate the effective and painless delivery of medications directly into the gastrointestinal wall. By replacing traditional injection methods, Biograil aims to enhance patient comfort and improve the administration of medications.
Mecuris
Series B in 2020
Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of customized orthopedic aids. The company's product range includes orthoses, prostheses, and related equipment, with notable offerings such as Mecuris FirStep, Mecuris NexStep, Mecuris cover, and the Mecuris Solution Platform. Mecuris aims to revolutionize the orthotics and prosthetics (O&P) industry by leveraging digital technology and 3D printing. Their platform uses patient data and scans to semi-automatically create individualized 3D designs for patient aids, which can be printed locally. This approach significantly reduces production times, enabling a fully customized fit, functionality, and appearance for wearers. Mecuris collaborates with O&P professionals to co-create these custom products, enhancing the lives of patients through innovative digital solutions.
Lindis Blood Care
Venture Round in 2019
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.
Laclarée
Seed Round in 2019
Laclarée is a French company based in Lyon, founded in 2016, that specializes in developing adaptive eyeglasses specifically designed to correct presbyopia. The company's innovative product incorporates patented fluid technology, allowing the eyeglasses to automatically adjust to different viewing distances in real-time. This advancement aims to address the needs of individuals aged 45 and older who are often dissatisfied with traditional vision correction solutions, such as progressive lenses or the use of multiple pairs of glasses. By combining adaptive lens technology with refractive correction capabilities for conditions like astigmatism, myopia, and hyperopia, Laclarée seeks to provide a more effective solution for clear vision across various distances.
Zahnarzt-Helden
Seed Round in 2019
Zahnarzt-Helden GmbH is a Bielefeld-based company that operates an online platform designed to assist dentists in identifying and acquiring essential dental equipment and services. Established in 2017, the company offers a diverse range of products, including Orthopantomograms, deep vein thrombosis scanners, Cephalometric devices, intraoral X-rays, intraoral scanners, autoclaves, thermodisinfectors, CAD/CAM systems, and management software. In addition to providing access to these products, Zahnarzt-Helden offers consultation services to help practitioners select the appropriate equipment, negotiate with manufacturers and dealers, and ensure reliable construction, maintenance, and long-term technical support. The platform aims to provide a transparent and user-friendly experience, akin to popular service comparators, allowing dental professionals to obtain favorable offers without hidden costs.
NAVAN Technologies
Seed Round in 2019
NAVAN Technologies, Inc. is a pre-clinical stage biotechnology company based in South San Francisco, California, founded in 2016. The company specializes in developing and commercializing its proprietary NanoStraw platform technology, which provides a direct and gentle means of accessing the cytosol of cells. This innovative platform addresses a significant challenge in the field of cell and gene therapies by enabling the efficient delivery of various cargoes into difficult-to-transfect cells without causing disruption. NAVAN's technology aims to enhance the capabilities of researchers and improve the effectiveness of therapeutic applications in biotechnology.
Mediaire
Seed Round in 2019
Mediaire GmbH is a Berlin-based company founded in 2018 that specializes in software solutions for medical imaging. Its flagship application, md.Brain, focuses on quantitative brain volumetry, facilitating early detection of senile dementia and the automated measurement of medullary lesions in multiple sclerosis patients. By leveraging artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, providing precise examination results and diagnostic suggestions. The software is designed to improve both the quality and speed of diagnostic and therapeutic procedures, making it a valuable tool for healthcare centers and radiologists.
Plasmion
Seed Round in 2019
Plasmion specializes in developing ionization devices for scientific and industrial applications. Its flagship product, the SICRIT SC-20X ionization set, is used across various sectors such as quality control, food safety, medical diagnosis, and emission monitoring. The company serves customers globally through its network of sales partners.
8sense
Seed Round in 2019
8sense develops a smart back sensor and coaching system for office use that combines wearable sensors to analyze posture and movement with real-time feedback and training. Through games and challenges, it motivates users to care for their backs, and the accompanying coaching platform provides science-based recommendations to promote an active, dynamic sitting posture for better back health.
Mecuris
Series A in 2019
Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of customized orthopedic aids. The company's product range includes orthoses, prostheses, and related equipment, with notable offerings such as Mecuris FirStep, Mecuris NexStep, Mecuris cover, and the Mecuris Solution Platform. Mecuris aims to revolutionize the orthotics and prosthetics (O&P) industry by leveraging digital technology and 3D printing. Their platform uses patient data and scans to semi-automatically create individualized 3D designs for patient aids, which can be printed locally. This approach significantly reduces production times, enabling a fully customized fit, functionality, and appearance for wearers. Mecuris collaborates with O&P professionals to co-create these custom products, enhancing the lives of patients through innovative digital solutions.
Kumovis
Seed Round in 2018
Kumovis is a medical technology company that specializes in developing a 3D printing system designed for both industrial and medical applications. The company focuses on the processing of high-performance polymers to create patient-customized implants. By integrating clean room technology into its 3D printing solutions, Kumovis enables hospitals to perform medical operations more conveniently and effectively, enhancing the overall quality of care.
Memetis
Venture Round in 2018
Memetis GmbH, established in 2017 and headquartered in Karlsruhe, Germany, specializes in the development and production of foil-based miniature actuators. These innovative products utilize shape memory alloy technology, offering superior force generation, compactness, and flexibility compared to traditional wire-based mechanisms. Memetis serves diverse industries such as automotive, aerospace, medical technology, bioanalytics, and testing equipment manufacturing, catering to their unique motion control needs. As a spin-off of Karlsruhe Institute of Technology (KIT), the company leverages cutting-edge research to deliver high-performance solutions tailored to each client's requirements.
GWA Hygiene
Venture Round in 2018
GWA Hygiene GmbH is a German company based in Stralsund, established in 2015, that specializes in the development of hygiene monitoring solutions for healthcare settings. The company manufactures sensors designed to monitor hand hygiene standards among hospital personnel and is expanding its offerings to include surface disinfection monitoring. GWA Hygiene's technology integrates with disinfectant and soap dispensers, equipping them with sensors to capture data on disinfection practices. This data can be displayed on monitors and is accessible via a software application that analyzes disinfection rates across different wards and professional groups. Users have the option to store data on their own servers or utilize GWA Hygiene's secure cloud storage. Additionally, the company's software toolbox aids in logistical tasks related to hygiene management, such as managing dispenser refills and device maintenance.
advanceCOR
Venture Round in 2018
advanceCOR is a clinical drug development company focused on therapeutics and diagnostics for heart and vascular diseases. Its activities span research, development, and plans for commercialization to enable personalized treatment of cardiovascular conditions. Lead candidates include Revacept, a human Fc fusion protein that prevents local platelet activation at sites of vascular injury; COR-2, a recombinant protein that interferes with foam cell formation and the uptake of cholesterol; and COR-3, a recombinant protein that binds to atherosclerotic plaques and bi-specifically captures circulating progenitor cells to promote plaque healing. The company also develops antibodies and fusion proteins targeting platelet receptors and other components involved in arterial thrombosis and plaque progression, with an emphasis on addressing acute events such as myocardial infarction and stroke.
Implandata Ophthalmic Products
Series C in 2018
Founded in 2010, Implandata specializes in developing innovative medical technologies for glaucoma management. Its flagship product is Eyemate, an implantable micro sensor that continuously measures intraocular pressure, improving glaucoma patient care.
Soley
Series A in 2018
Soley is a software company that develops analytics and management software for engineering and product development. It offers products for domain-specific modeling, data intelligence, and automated analytics, including tools for data quality, visualization, and deploying tailored applications. The platform integrates data from development, purchasing, manufacturing, and sales to help product managers optimize portfolios, automate workflows, and manage complexity. Applications cover change management, verification and validation, test-case management, and product architecture analysis, enabling informed decision making. The company serves automotive, consumer goods, medical equipment, IT, and electronics industries, with activities in Germany and international markets.
RIMASYS
Venture Round in 2017
RIMASYS is dedicated to advancing surgical education and medical technology research and development. The company focuses on creating realistic fractures in human specimens through a unique algorithm and device, which supports practical skill training for surgeons. By integrating digital learning, virtual reality, and 3D printing, RIMASYS aims to improve patient outcomes and enhance the quality of life for individuals requiring advanced therapies and operations. Their innovative approach facilitates collaboration among medical science, academia, and industry, fostering the development of better implants and surgical techniques.
ReActive Robotics
Series B in 2017
Founded in 2015, ReActive Robotics designs, manufactures, and sells rehabilitation robots for early movement rehabilitation post neurological injury or orthopedic surgery. Its robots aid in gait rehabilitation for neurological patients and joint replacement recovery.
KSK Diagnostics
Series A in 2017
KSK Diagnostics GmbH, founded in 2014 and based in Hamburg, Germany, specializes in the development of molecular point-of-care diagnostic assays. The company focuses on creating tests for the molecular diagnosis of infectious diseases and cancer, utilizing innovative isothermal amplification technology. These assays are designed to provide rapid results, allowing healthcare professionals to make timely diagnoses and coordinate treatment plans effectively, often within 30 minutes. In addition to its core diagnostic products, KSK Diagnostics offers customizable services for nucleic acid-based test development, including real-time PCR and RT-PCR, as well as verification, validation studies, and product enhancement services for other organizations. As a pioneering entity in its field, KSK Diagnostics is committed to advancing patient-oriented diagnostics.
Whitesonic
Seed Round in 2016
Whitesonic is a medical technology company specializing in digital dentistry solutions. It develops an ultrasound-based scanner designed for non-invasive, radiation-free dental impressions by utilizing high-frequency acoustic waves. This enables dentists to efficiently record and prepare dental data and soft tissue information. The company aims to advance its scanner prototype through further development, with plans to use it on patients as early as 2017 following successful evaluation phases.
Mecuris
Seed Round in 2016
Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of customized orthopedic aids. The company's product range includes orthoses, prostheses, and related equipment, with notable offerings such as Mecuris FirStep, Mecuris NexStep, Mecuris cover, and the Mecuris Solution Platform. Mecuris aims to revolutionize the orthotics and prosthetics (O&P) industry by leveraging digital technology and 3D printing. Their platform uses patient data and scans to semi-automatically create individualized 3D designs for patient aids, which can be printed locally. This approach significantly reduces production times, enabling a fully customized fit, functionality, and appearance for wearers. Mecuris collaborates with O&P professionals to co-create these custom products, enhancing the lives of patients through innovative digital solutions.
Immunic Therapeutics
Series A in 2016
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.
CryoTherapeutics
Series B in 2016
CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in the development of a proprietary cryotherapy system aimed at treating coronary artery disease, a major cause of heart attacks. The company focuses on demonstrating the clinical benefits and ensuring the safety and efficacy of cryoenergy in the cardiovascular system. Its novel catheter system utilizes cryo energy to treat and prevent heart attacks, offering a promising approach to addressing the challenges posed by diseased coronary arteries. Through its early-stage commercialization efforts, CryoTherapeutics aims to enhance treatment options for heart surgeons and improve patient outcomes in cardiovascular health.
ReActive Robotics
Series A in 2016
Founded in 2015, ReActive Robotics designs, manufactures, and sells rehabilitation robots for early movement rehabilitation post neurological injury or orthopedic surgery. Its robots aid in gait rehabilitation for neurological patients and joint replacement recovery.
Cevotec
Seed Round in 2016
Cevotec GmbH, founded in 2015 and headquartered in Munich, Germany, specializes in the design and automation of carbon fiber composites using its proprietary Fiber Patch Placement technology. The company provides manufacturers with SAMBA systems for the fully automated production of complex 3D geometries and multi-material laminates. These systems facilitate significant cost and time savings, ranging from 20% to 60%, compared to traditional manual layup methods. Cevotec also offers ARTIST STUDIO, a CAD-CAM software tailored for generating patch-based fiber laminates and automating robot programming. Serving various industries, including aerospace, medical devices, and sports, Cevotec enhances product development by enabling the creation of advanced composite materials with improved mechanical properties and reduced development times. Additionally, the company supports its clients through a comprehensive service portfolio that includes custom solutions and finite element-based component development.
CorTec
Series B in 2016
CorTec specializes in developing innovative medical devices for neuromodulation and brain-computer interfaces. Its flagship product is the CorTec Brain Interchange™ System, featuring flexible electrode arrays and a hermetically sealed electronics unit with custom microchip technology. The system enables permanent brain recordings and stimulation without the need for battery replacement surgery.
SeNostic Health GmbH
Seed Round in 2016
SeNostic is a diagnostics company focused on developing innovative in vitro diagnostic tests for neurodegenerative disorders. The company aims to provide precise and accurate early differential diagnoses for various neurodegenerative conditions, enhancing the ability to identify specific diseases. SeNostic also specializes in offering biochemicals for neuroscience research and has created a novel method to amplify and characterize disease-specific protein aggregates found in tissues and body fluids. This approach enables better patient outcomes by facilitating timely and appropriate treatment for those affected by neurodegenerative diseases.
Abviris Deutschland
Seed Round in 2016
Abviris Deutschland GmbH is a German company founded in 2014, specializing in the development, manufacture, and marketing of in-vitro diagnostics and medical devices aimed at addressing oral cancer. Based in Ammersbek, the company focuses on utilizing immunologically active components, including a variety of antibodies targeting different types of human papilloma virus (HPV) and relevant antigens. One of its key products is PrevO-Check, an in-vitro diagnostic medical device designed for the screening of HPV-induced oral cavity cancer. Abviris Deutschland addresses the challenge of early detection, particularly since HPV infections often do not exhibit early symptoms, leading to late-stage diagnoses. The company's innovations aim to improve screening processes, especially in areas of the oral cavity that are not typically examined during standard dental visits.
Multiphoton Optics
Series A in 2015
Multiphoton Optics GmbH, founded in September 2013 and based in Würzburg, Germany, specializes in the development and sale of 3D printing equipment and software solutions for additive manufacturing. The company’s technology enables the creation of intricate three-dimensional structures on various materials, including polymers, hybrid materials, glasses, and metals. Its flagship products include the LithoProf3D printing platform, along with software solutions such as LithoStream3D and LithoSoft3D, which support applications in photonics, biomedicine, life sciences, and functional materials. Additionally, Multiphoton Optics offers high-precision automation processes for opto-electronics assembly, facilitating the interconnection of optical components and photonic chips. The company also provides prototyping, engineering support, and consulting services to enhance its customers' capabilities.
Bomedus
Series B in 2015
Bomedus is a Germany-based medical device company founded in 2011, focused on improving mobility for individuals suffering from chronic back pain. The company develops innovative devices that utilize an electro-therapeutic method to provide permanent and sustainable pain reduction. By non-invasively modulating pathologically altered neuronal impulses, Bomedus aims to enhance the quality of life for patients dealing with pain-related challenges.
Soley
Seed Round in 2015
Soley is a software company that develops analytics and management software for engineering and product development. It offers products for domain-specific modeling, data intelligence, and automated analytics, including tools for data quality, visualization, and deploying tailored applications. The platform integrates data from development, purchasing, manufacturing, and sales to help product managers optimize portfolios, automate workflows, and manage complexity. Applications cover change management, verification and validation, test-case management, and product architecture analysis, enabling informed decision making. The company serves automotive, consumer goods, medical equipment, IT, and electronics industries, with activities in Germany and international markets.
Venneos
Seed Round in 2015
Venneos GmbH is a high-tech startup based in Stuttgart, Germany, founded in 2014 as a spin-off from the Max Planck Society. The company specializes in developing a silicon chip-based imaging system known as 'CAN-Q' for the label-free analysis of biological cells. This innovative technology, based on CAN-Spectroscopy, allows researchers to detect cellular changes that are typically invisible to other imaging technologies. Venneos' products cater to various fields, including tumor biology, immunology, and pharmacology, providing valuable insights to researchers in academia as well as professionals in the pharmaceutical and biotech industries.
Eyetronic Therapie
Venture Round in 2015
EBS Technologies GmbH, founded in 2007 and headquartered in Hennigsdorf, Germany, specializes in developing and commercializing medical devices aimed at treating neurologically induced impairments, particularly visual field loss. The company offers EBS Therapy, a non-invasive optic nerve stimulation treatment that utilizes low-voltage electrical currents to promote neuroregeneration and neuroprotection. This therapy targets conditions resulting from stroke, traumatic brain injury, and glaucoma, among others. With over 15 years of research and clinical experience involving more than 1,200 patients, EBS Technologies has demonstrated through double-blind, randomized studies and clinical observations that its therapy can help partially restore vision in affected individuals. The company received the CE Mark for its stimulation device in 2013 and commenced commercial treatments in 2014. Currently, there are eight EBS Treatment centers operating across Germany, with plans to expand the network further.
oncgnostics
Series A in 2015
oncgnostics GmbH is a German company specializing in molecular diagnostics, particularly focused on developing in vitro diagnostic (IVD) tests for cancer. Founded in 2012 and based in Jena, oncgnostics utilizes proprietary epigenetic biomarkers to create reliable assays that facilitate early detection and diagnosis of cervical cancer and its precursors. The company's flagship product, GynTect, offers a swift and accurate method for identifying cervical cancer and pre-cancerous conditions. By targeting specific DNA regions that are methylated in precancerous and cancerous cells, oncgnostics employs established PCR-based technologies suitable for routine use in molecular diagnostics laboratories. This innovative approach not only aids in screening but also supports therapeutic decision-making and follow-up care, aiming to improve patient outcomes through early intervention.
Implandata Ophthalmic Products
Series B in 2014
Founded in 2010, Implandata specializes in developing innovative medical technologies for glaucoma management. Its flagship product is Eyemate, an implantable micro sensor that continuously measures intraocular pressure, improving glaucoma patient care.
Preventicus
Seed Round in 2014
Founded in 2014 and headquartered in Jena, Germany, Preventicus develops certified medical device software for smartphones and smartwatches. Its primary product, Preventicus Heartbeats, identifies atrial fibrillation for stroke prevention by analyzing patients' vital parameters, enabling early detection of lifestyle-related illnesses.
Medineering
Seed Round in 2014
Medineering is a medical technology company based in Munich, Germany, that focuses on developing and marketing innovative robotic systems for minimally invasive head surgery. Founded in 2014, the company offers a modular portfolio of surgical manipulators, enabling clinics and surgeons to select the level of automation and functionality that aligns with their surgical needs and budgetary considerations. Medineering's product line includes an intelligent positioning arm and compact, application-specific robots designed to assist surgeons in navigating complex anatomical regions. The company's mission is to enhance the capabilities of minimally invasive surgery through advanced robotic solutions tailored to specific surgical tasks and environments.
Coramaze Technologies
Seed Round in 2014
Founded in 2013 and headquartered in Munich, Germany, Coramaze Technologies is a medical device company developing minimally invasive solutions for heart valve repair. Their flagship product, the Tripair implant, is designed to treat functional tricuspid regurgitation by anchoring adaptively in the right atrium, enabling a quick and simple procedure accessible to a wide patient population.
Scopis
Series A in 2013
Scopis GmbH, founded in 2010 and based in Berlin, Germany, specializes in the development and manufacture of navigation systems for minimally invasive surgeries. The company offers a range of products including the Scopis TGS for navigated functional endoscopic sinus surgery and the Hybrid Navigation System, which integrates with endoscopic towers to provide HD documentation capabilities. Scopis also produces a variety of surgical instruments and accessories designed for applications in ENT, spine, cranio-maxillofacial (CMF), and neurosurgery. Their offerings include EM instruments, malleable suction tubes, sensor-equipped instruments, and various tracking and mounting devices. Additionally, Scopis provides Building Blocks Planning Software, which facilitates the planning and execution of surgical procedures. As a subsidiary of Stryker Corporation, Scopis maintains a global distribution network and has a strong focus on enhancing navigation technologies, particularly in endoscopic surgery, through innovations such as their augmented reality navigation system, MATRIX POLAR AR.
Synoste
Venture Round in 2013
Synoste Oy, founded in 2007 and based in Espoo, Finland, specializes in innovative medical solutions for correcting skeletal deformities. The company focuses on developing a third-generation limb-lengthening system aimed at improving the conventional, often uncomfortable, procedures associated with bone-lengthening and deformation correction. By leveraging smart materials, Synoste’s technology aims to provide a less painful experience for patients while enhancing the precision and control of the treatment process. This approach not only reduces complication rates but also facilitates a quicker recovery, allowing patients to return to their normal activities sooner. Operating as a subsidiary of Globus Medical, Inc., Synoste addresses various conditions, including congenital and trauma-related limb discrepancies, as well as craniomaxillofacial deformations.
dentaZOOM
Seed Round in 2013
dentaZOOM is a company that specializes in the development and distribution of compact surgical microscopes specifically designed for dental procedures. Their microscopes are characterized by a lightweight and small design, allowing for easy integration into various stages of treatment. Each unit features a monocular design with an integrated LED light system, which enhances visibility and precision during dental surgeries. This innovative approach facilitates a seamless experience for dental professionals, enabling them to perform procedures more effectively while minimizing inconvenience for their patients.
Photonics Healthcare
Venture Round in 2013
Photonics Healthcare GmbH is a medical device company based in Garching, Germany, specializing in the development and commercialization of clinical monitors for cellular oxygen measurement. The company's flagship product, the COMET Monitor, enables healthcare professionals to assess cellular oxygen metabolism, including the availability and consumption of oxygen in tissue cells. This non-invasive device provides critical data at the bedside, allowing doctors to detect hypoxia early, evaluate tissue vitality, and make informed decisions regarding treatment interventions. By accurately measuring mitochondrial oxygen availability and tension, Photonics Healthcare aims to enhance patient care and prevent potential organ failure, thereby improving the overall effectiveness of medical interventions. Additionally, the company offers contract research programs to support further advancements in the field.
PERORA
Seed Round in 2013
PERORA GmbH is a biotechnology company based in Heidelberg, Germany, that focuses on developing innovative solutions for weight management and obesity treatment. Established in 2013, the company has created a polymer-based fat-binding medical device and has also produced REDIA, a nutritional supplement that is clinically validated for lowering postprandial blood sugar levels in type 2 diabetes patients. REDIA is the first supplement with a health claim approved in the European Union and the United States, and the company holds patents for this product in multiple countries. PERORA is strategically positioning itself to build a subscription-based business model for self-management of chronic age-related metabolic health within Europe, with plans to expand its licensing efforts internationally.
NovaPump
Seed Round in 2013
NovaPump specializes in developing non-invasive and percutaneous heart assist devices. Its flagship product is PERKAT, a self-expanding heart pump designed for acute left or right heart patients. PERKAT complements existing intra-aortic balloon pumps and offers advantages such as high pump performance, cost-effectiveness, and ECG triggering.
Middle Peak Medical
Series A in 2013
Middle Peak Medical is a privately held medical device company dedicated to addressing mitral valve disease through innovative technology. The company develops a proprietary device designed for both percutaneous catheter-based interventions and minimally invasive or open-heart surgical procedures. This novel device specifically targets the treatment of mitral valve regurgitation, aiming to restore proper mitral valve function in cases of both functional and degenerative conditions. By providing a new posterior surface for the anterior leaflet to seal effectively, Middle Peak Medical seeks to meet critical unmet needs in the management of mitral valve diseases.
Eyetronic Therapie
Series B in 2013
EBS Technologies GmbH, founded in 2007 and headquartered in Hennigsdorf, Germany, specializes in developing and commercializing medical devices aimed at treating neurologically induced impairments, particularly visual field loss. The company offers EBS Therapy, a non-invasive optic nerve stimulation treatment that utilizes low-voltage electrical currents to promote neuroregeneration and neuroprotection. This therapy targets conditions resulting from stroke, traumatic brain injury, and glaucoma, among others. With over 15 years of research and clinical experience involving more than 1,200 patients, EBS Technologies has demonstrated through double-blind, randomized studies and clinical observations that its therapy can help partially restore vision in affected individuals. The company received the CE Mark for its stimulation device in 2013 and commenced commercial treatments in 2014. Currently, there are eight EBS Treatment centers operating across Germany, with plans to expand the network further.
Dolosys
Venture Round in 2013
Dolosys GmbH is a Berlin-based medical technology company specializing in the development and production of devices for the objective measurement of pain and pain management. The company focuses on creating innovative equipment that assists healthcare providers in monitoring and controlling pain, particularly for sedated intensive care patients and individuals suffering from chronic pain. By optimizing pain therapy, Dolosys aims to enhance pain management alternatives available to healthcare organizations, ultimately improving patient care and outcomes.
WISE
Venture Round in 2013
WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper.
CryoTherapeutics
Series A in 2013
CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in the development of a proprietary cryotherapy system aimed at treating coronary artery disease, a major cause of heart attacks. The company focuses on demonstrating the clinical benefits and ensuring the safety and efficacy of cryoenergy in the cardiovascular system. Its novel catheter system utilizes cryo energy to treat and prevent heart attacks, offering a promising approach to addressing the challenges posed by diseased coronary arteries. Through its early-stage commercialization efforts, CryoTherapeutics aims to enhance treatment options for heart surgeons and improve patient outcomes in cardiovascular health.
Advanova
Series A in 2013
Founded in 2012, Advanova develops VMobil software that enables medical professionals to access a patient’s complete electronic record on mobile devices. Based in Erlangen, Germany.
Drug Response Dx
Series A in 2013
Drug Response Dx is a biotechnology company located in Hennigsdorf, Germany, founded in February 2012 by a team of experts including Dr. Zoltán Konthur, Dr. Jörg-M. Hollidt, Dr. Karl Skriner, and Dr. Joachim Rautter. The company specializes in developing biomarker tests specifically designed to evaluate treatment outcomes for rheumatoid arthritis (RA). Its tests focus on a protein that predicts the effectiveness of TNF-alpha inhibitors for individual patients prior to initiating medication. This approach facilitates timely treatment decisions and enhances the likelihood of successful therapeutic outcomes for patients suffering from RA. The company has established proof of concept using serum samples from RA patients, and its biomarker set is prevalidated, ensuring the reliability of its testing processes.
InnoCyte
Series A in 2012
InnoCyte - Technologies for automated Cell Culture. They have the strong belief that automated cell culture could be of inestimable value for cell processing in labs all over the world. InnoCyte brings automated cell culture to the masses - within a benchtop designed, reliable and affordable device.
JeNaCell
Seed Round in 2012
JeNaCell GmbH, founded in 2012 and based in Jena, Germany, specializes in biotechnology, focusing on the development and manufacture of bio-technologically derived cellulose. The company has created a patented technology for the continuous production of high-performance biomaterials featuring natural nanostructures. This innovative nano cellulose is characterized by its defined shape and controllable structural design, allowing clients to develop advanced products in medicine, cosmetics, technology, and pharmaceuticals. JeNaCell's offerings aim to enhance skin protection, particularly in the treatment of chronic wounds, and support applications in laser treatments and aesthetic dermatology.
Topsfield Medical GmbH
Seed Round in 2012
Topsfield Medical GmbH is a Berlin-based orthopedic start-up founded in 2012. The company focuses on developing innovative medical devices aimed at extending the life of implants. Its primary objective is to tackle the critical issue of premature implant loosening by enhancing the fixation methods used in prostheses. Through its advancements, Topsfield Medical aims to improve patient outcomes and contribute to the field of orthopedics.
oncgnostics
Seed Round in 2012
oncgnostics GmbH is a German company specializing in molecular diagnostics, particularly focused on developing in vitro diagnostic (IVD) tests for cancer. Founded in 2012 and based in Jena, oncgnostics utilizes proprietary epigenetic biomarkers to create reliable assays that facilitate early detection and diagnosis of cervical cancer and its precursors. The company's flagship product, GynTect, offers a swift and accurate method for identifying cervical cancer and pre-cancerous conditions. By targeting specific DNA regions that are methylated in precancerous and cancerous cells, oncgnostics employs established PCR-based technologies suitable for routine use in molecular diagnostics laboratories. This innovative approach not only aids in screening but also supports therapeutic decision-making and follow-up care, aiming to improve patient outcomes through early intervention.
KonTEM
Venture Round in 2012
KonTEM is a technology company specializing in the development of phase contrast systems for transmission electron microscopes. These innovative systems significantly enhance image quality, particularly benefiting applications in the fields of Life Sciences and Soft Materials. By improving the capability of electron microscopy, KonTEM aims to facilitate advanced research and analysis, enabling clients to achieve clearer and more detailed imaging results.
Seiratherm
Venture Round in 2012
Seiratherm is a privately held medical technology company located in Herzogenaurach, Germany, specializing in fluid and body-temperature management devices. The company's innovative devices are designed to quickly and safely regulate the core body temperature of critically ill or surgical patients, targeting pre-set treatment goals. By effectively managing body temperature, Seiratherm's devices help lower metabolic rates, which can reduce neurological damage and enhance the treatment of conditions such as hypothermia, normothermia, and hyperthermia. This approach enables healthcare professionals to deliver more efficient and effective care to patients in critical situations.
Implandata Ophthalmic Products
Series A in 2012
Founded in 2010, Implandata specializes in developing innovative medical technologies for glaucoma management. Its flagship product is Eyemate, an implantable micro sensor that continuously measures intraocular pressure, improving glaucoma patient care.
Eyesight & Vision GmbH
Seed Round in 2011
Eyesight & Vision GmbH, founded in 2010 and based in Nürnberg, Germany, specializes in the development and marketing of advanced diagnostic equipment for refractive error measurement during cataract surgery. The company's flagship product, the Intraoperative Ocular Wavefront Aberrometer (I-O-W-A), enhances surgical precision by providing surgeons with real-time data on the refractive power of the eye and the positioning of intraocular lenses (IOLs). This innovative system employs patented "flying spot" technology, facilitating rapid and reliable measurements that integrate seamlessly with existing surgical microscopes. Eyesight & Vision GmbH focuses on optimizing the selection and placement of IOLs, ultimately aiming to improve patient outcomes and satisfaction in refractive cataract and lens surgeries.
German Medical Engineering
Venture Round in 2011
GME German Medical Engineering GmbH, founded in 2011 and based in Erlangen, Germany, specializes in the development and marketing of laser and light systems for dermatological applications. The company offers a range of products, including the Linscan 808 diode laser, which is designed for effective hair removal without the need for anesthetics or gels, as well as treatments for conditions such as psoriasis and vitiligo. GME's systems are characterized by their ease of installation, user-friendly software, and compact design, making them suitable for both aesthetic and medical uses. The equipment is developed and manufactured in Germany, adhering to high standards of medical device approval and monitoring. GME markets its innovative solutions globally through partner companies, aiming to enhance the capabilities of medical professionals in treating various skin conditions.
Humedics
Series A in 2011
Humedics develops a breath analysis device that measures liver function in real-time. Its LiMAx test enables clinicians to quantitatively determine individual liver function capacity, supporting treatment decisions and improving patient outcomes. The company focuses on applications such as liver transplantation diagnosis, living donor assessment, and disease evaluation.
CorTec
Seed Round in 2011
CorTec specializes in developing innovative medical devices for neuromodulation and brain-computer interfaces. Its flagship product is the CorTec Brain Interchange™ System, featuring flexible electrode arrays and a hermetically sealed electronics unit with custom microchip technology. The system enables permanent brain recordings and stimulation without the need for battery replacement surgery.
Microstim
Venture Round in 2011
Microstim GmbH specializes in the development of implantable myostimulators aimed at assisting cardiac function while preserving tissue integrity. The company's innovative device enables muscle-powered cardiac assistance, allowing patients to monitor stimulation loads and mitigate the risks associated with overstimulation. Microstim's strengths lie in its advanced microcontroller technology, which facilitates the acquisition and processing of data, as well as the control of cardiac and muscle stimulator impulses. Additionally, the device features wireless communication capabilities for in-body monitoring. In recognition of its innovative approach, Microstim was honored as one of the winners in the concept phase category at the national business plan contest "Science4Life" in 2008.
Transcatheter Technologies
Series A in 2011
TRANSCATHETER TECHNOLOGIES is developing a unique aortic valve implantation system that will increase the safety and durability of aortic valve implantation. The TRINITY repositionable transcatheter aortic valve system is at the forefront of next-generation transcatheter valve implantation technology. In the near future, transcatheter valve implantation will become the preferred therapy for aortic valve implantation, and TRANSCATHETER TECHNOLOGIES‘ goal is to provide the most advanced technology available.
SAW Instruments
Series B in 2011
SAW Instruments is a manufacturer and distributor specializing in innovative analytical systems for the life sciences market. Its products enable label-free analysis of molecular biomolecular interactions, combining stability, ease of use, and high sensitivity. These instruments are successfully employed by prominent research institutions in Germany and Switzerland.
Gilupi
Series C in 2011
GILUPI GmbH is a medical device company based in Potsdam, Germany, specializing in the development and production of diagnostic products aimed at the in vivo isolation of rare cells from circulating blood. The company's primary focus is on isolating tumor cells, utilizing devices that employ predetermined selectivity of antibodies bound to nano-detectors. This technology enables healthcare professionals to effectively isolate circulating tumor cells within patients' blood, facilitating more precise diagnoses and tailored therapeutic interventions. GILUPI's devices are CE certified, ensuring their compliance with safety and efficacy standards, which enhances their credibility and utility in clinical settings.
Heppe Medical Chitosan
Series B in 2010
Heppe Medical Chitosan GmbH is a German company based in Halle that specializes in the development, production, and sale of biopolymers and nanoparticles derived from chitin and chitosan. Founded in 2005, the company operates under Good Manufacturing Practice (GMP) conditions, ensuring high-quality standards in its products. Heppe Medical Chitosan produces pure chitin, chitosan, and their derivatives, which are utilized in various applications within the cosmetic and pharmaceutical industries. The company’s biopolymers and nanoparticles are biodegradable, non-toxic, and exhibit bacteriostatic properties, making them suitable for use in wound dressings, drug delivery systems, and tissue engineering. Through its innovative approach, Heppe Medical Chitosan contributes to the advancement of sustainable materials in healthcare and beauty applications.
Curefab Technologies
Venture Round in 2010
Curefab Technologies is a developer of advanced medical technologies focused on the objective quantitative assessment of diagnostic image data. The company's innovations enhance diagnostic certainty, facilitating early detection of cardiovascular and oncological diseases. Curefab's technologies play a crucial role in stroke prevention, the early diagnosis of vascular conditions, and the monitoring of cancer therapies. Additionally, the company offers computed sonography systems that allow for the comparison and analysis of ultrasound images, thereby providing physicians with relevant diagnostic parameters essential for patient care.
Scopis
Seed Round in 2010
Scopis GmbH, founded in 2010 and based in Berlin, Germany, specializes in the development and manufacture of navigation systems for minimally invasive surgeries. The company offers a range of products including the Scopis TGS for navigated functional endoscopic sinus surgery and the Hybrid Navigation System, which integrates with endoscopic towers to provide HD documentation capabilities. Scopis also produces a variety of surgical instruments and accessories designed for applications in ENT, spine, cranio-maxillofacial (CMF), and neurosurgery. Their offerings include EM instruments, malleable suction tubes, sensor-equipped instruments, and various tracking and mounting devices. Additionally, Scopis provides Building Blocks Planning Software, which facilitates the planning and execution of surgical procedures. As a subsidiary of Stryker Corporation, Scopis maintains a global distribution network and has a strong focus on enhancing navigation technologies, particularly in endoscopic surgery, through innovations such as their augmented reality navigation system, MATRIX POLAR AR.
Implandata Ophthalmic Products
Seed Round in 2010
Founded in 2010, Implandata specializes in developing innovative medical technologies for glaucoma management. Its flagship product is Eyemate, an implantable micro sensor that continuously measures intraocular pressure, improving glaucoma patient care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.